#1 Clinical Trials Search in Europe

Technetium (99Mtc) Certolizumab Pegol

This article discusses a clinical trial investigating the use of Technetium (99Mtc) Certolizumab Pegol in patients with axial spondyloarthritis (axSpA). The study aims to improve treatment strategies by incorporating immunoscintigraphy, a specialized imaging technique, into the existing decision-making process for axSpA patients. This innovative approach may help better assess disease activity and predict treatment response, potentially leading to more effective and personalized care for individuals with this chronic inflammatory condition.

Table of Contents

What is TECHNETIUM (99MTC) CERTOLIZUMAB PEGOL?

TECHNETIUM (99MTC) CERTOLIZUMAB PEGOL is a new radiopharmaceutical being studied for its potential in treating and diagnosing axial spondyloarthritis. It is also known as 99mTc Certolizumab Pegol or 99mTc HyNic Certolizumab Pegol.[1] This medication combines two key components:

  1. Certolizumab pegol: A biologic drug used to treat various inflammatory conditions.
  2. Technetium-99m: A radioactive isotope commonly used in medical imaging.

This combination allows doctors to both treat the condition and visualize the areas of inflammation in the body using a special imaging technique called immunoscintigraphy.[1]

What is Axial Spondyloarthritis?

Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the spine and sacroiliac joints (where the spine connects to the pelvis). It can cause chronic back pain, stiffness, and over time, may lead to fusion of the spine’s bones. This condition can significantly impact a person’s quality of life and mobility.[1]

How Does TECHNETIUM (99MTC) CERTOLIZUMAB PEGOL Work?

TECHNETIUM (99MTC) CERTOLIZUMAB PEGOL works in two ways:

  1. Treatment: The certolizumab pegol component is a biologic drug that helps reduce inflammation in the body.
  2. Diagnosis: The technetium-99m component allows doctors to use a special camera to see where the medication is concentrating in the body, highlighting areas of inflammation.

This dual action could potentially improve how doctors assess disease activity and predict treatment response in patients with axial spondyloarthritis.[1]

Clinical Trial Overview

A Phase III clinical trial is currently being conducted to evaluate the effectiveness of including TECHNETIUM (99MTC) CERTOLIZUMAB PEGOL in the treatment strategy for axial spondyloarthritis. The main goal of this study is to determine if using immunoscintigraphy (a type of imaging that uses this medication) can improve how doctors assess disease activity and predict treatment response.[1]

The trial aims to compare the results of the current treatment decision-making process with a new approach that includes immunoscintigraphy. Researchers will look at how well patients respond to treatment after 12 and 24 weeks.[1]

Who Can Participate in the Trial?

The trial is looking for participants who meet certain criteria, including:

  • Adults aged 18 to 85 years old
  • Diagnosed with axial spondyloarthritis
  • Have not responded well to initial treatments like NSAIDs (non-steroidal anti-inflammatory drugs)
  • Meet Belgian reimbursement criteria for starting advanced therapies (bDMARDs or tsDMARDs)
  • Have had an MRI within the last 3 months
  • Have elevated levels of C-reactive protein (CRP), a marker of inflammation

There are also several factors that would exclude someone from participating, such as certain other medical conditions or recent use of specific medications.[1]

What to Expect During the Trial

If you participate in the trial, you can expect the following:

  • You will receive TECHNETIUM (99MTC) CERTOLIZUMAB PEGOL as an intravenous injection (into a vein).
  • You will undergo immunoscintigraphy, which involves lying still while a special camera takes pictures of your body.
  • Your disease activity will be monitored using standardized questionnaires and blood tests.
  • You will be followed for at least 24 weeks to assess your response to treatment.
  • Your results will be compared with those of other participants to determine the effectiveness of this new approach.

The maximum dose of the medication used in the trial is 814 MBq (megabecquerels, a measure of radioactivity).[1]

Potential Benefits and Risks

Potential benefits of this new approach include:

  • More accurate assessment of disease activity
  • Better prediction of treatment response
  • Improved treatment decisions
  • Potentially better outcomes for patients

However, as with any medical procedure involving radiation, there are potential risks. The use of radioactive materials is carefully controlled, and the amount used in this study is considered low. Nonetheless, participants should discuss all potential risks and benefits with their healthcare provider before deciding to participate in the trial.[1]

Aspect Details
Study Title Optimizing treatment strategy in axial spondyloarthritis by molecular imaging with Technetium-labeled certolizumab pegol
Main Objective To improve assessment of disease activity and prediction of treatment response in axSpA using immunoscintigraphy
Study Drug Technetium (99Mtc) Certolizumab Pegol
Primary Endpoint Difference in response rates between patients with positive and negative immunoscintigraphy at 12 weeks
Key Inclusion Criteria Adults 18-85 years, diagnosed with axSpA, meeting specific health criteria
Key Exclusion Criteria Contraindications to bDMARDs or tsDMARDs, severe infections, pregnancy, recent experimental therapies
Study Duration Key assessments at 12 and 24 weeks after treatment initiation

FAQ

  • What is the main goal of this clinical trial? The main goal is to determine if including immunoscintigraphy in the existing therapeutic decision algorithm for axial spondyloarthritis (axSpA) improves the assessment of disease activity and prediction of treatment response to immunomodulating agents at 12 weeks after starting treatment.
  • Who can participate in this clinical trial? Participants must be between 18 and 85 years old, diagnosed with axial spondyloarthritis, meet Belgian reimbursement criteria for starting certain medications, have a recent MRI, and show insufficient response to first-line treatment. They must also meet other specific health criteria and provide informed consent.
  • What is Technetium (99Mtc) Certolizumab Pegol used for in this study? Technetium (99Mtc) Certolizumab Pegol is used as a radiopharmaceutical for immunoscintigraphy, which is an imaging technique. This helps visualize inflammation in the body and may improve the assessment of disease activity in axial spondyloarthritis patients.
  • How long does the study last for each participant? The study evaluates participants at several time points, with key assessments at 12 weeks and 24 weeks after starting treatment. The total duration of participation may vary depending on individual factors and study protocols.
  • What are some of the potential benefits of this research? This research may lead to improved treatment strategies for axial spondyloarthritis by enhancing the ability to predict treatment response and assess disease activity. It could result in more personalized and effective care for patients, potentially improving their quality of life and long-term outcomes.

Ongoing Clinical Trials on Technetium (99Mtc) Certolizumab Pegol

  • Study on Axial Spondyloarthritis Treatment Using Technetium-Labeled Certolizumab Pegol for Patients with Axial Spondyloarthritis

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Axial Spondyloarthritis (axSpA): A type of inflammatory arthritis that primarily affects the spine and sacroiliac joints, causing chronic back pain and stiffness.
  • Immunoscintigraphy: An imaging technique that uses radioactively labeled antibodies to visualize specific tissues or inflammation in the body.
  • Technetium (99Mtc) Certolizumab Pegol: A radiopharmaceutical used in this study, combining a radioactive isotope (Technetium-99m) with certolizumab pegol, a medication used to treat certain inflammatory conditions.
  • bDMARD: Biological Disease-Modifying Antirheumatic Drug, a type of medication that targets specific components of the immune system to reduce inflammation and slow disease progression.
  • tsDMARD: Targeted Synthetic Disease-Modifying Antirheumatic Drug, a newer class of medications that target specific molecules involved in the inflammatory process.
  • ASDAS: Ankylosing Spondylitis Disease Activity Score, a measure used to assess disease activity in axial spondyloarthritis.
  • ASAS 40 response: Assessment of Spondyloarthritis International Society 40 response, a measure of improvement in disease symptoms and signs.
  • CRP: C-Reactive Protein, a blood test marker that indicates the level of inflammation in the body.
  • ESR: Erythrocyte Sedimentation Rate, another blood test that measures inflammation levels in the body.
  • MRI: Magnetic Resonance Imaging, a non-invasive imaging technique used to visualize internal body structures and detect inflammation.

References

  1. http://clinicaltrials.eu/trial/study-on-axial-spondyloarthritis-treatment-using-technetium-labeled-certolizumab-pegol-for-patients-with-axial-spondyloarthritis/